# Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

> **NCT06904300** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 110 (estimated)

## Conditions studied

- Gastric (Cardia, Body) Cancer

## Interventions

- **DRUG:** AK112 + paclitaxel
- **DRUG:** Paclitaxel ± ramucirumab

## Key facts

- **NCT ID:** NCT06904300
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904300, "Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06904300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*